Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.
about
Synthesis and Anti-Hepatitis B Virus and Anti-Hepatitis C Virus Activities of 7-Deazaneplanocin A Analogues in VitroIntracellular metabolism of beta-L-2',3'-dideoxyadenosine: relevance to its limited antiviral activityAnti-Epstein-Barr virus (EBV) activity of beta-L-5-iododioxolane uracil is dependent on EBV thymidine kinaseAntiviral L-nucleosides specific for hepatitis B virus infectionInhibition of episomal hepatitis B virus DNA in vitro by 2,4-diamino-7- (2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-pyrrolo[2,3-d]pyrimidineInhibition of replication of hepatitis B virus by cytallene in vitroInhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracilSynthesis and biological evaluation of 1,3-oxathiolane 5-azapyrimidine, 6-azapyrimidine, and fluorosubstituted 3-deazapyrimidine nucleosides.Synthesis and enantioselectivity of the antiviral effects of (R,Z)-,(S,Z)-methylenecyclopropane analogues of purine nucleosides and phosphoralaninate prodrugs: influence of heterocyclic base, type of virus and host cells.Synthesis and antiviral activity of C-5 substituted beta-D- and beta-L-D4T analogues.Characterization of a novel D-lyxose isomerase from Cohnella laevoribosii RI-39 sp. nov.Virologic and biochemical responses to clevudine in patients with chronic HBV infection-associated cirrhosis: data at week 48.Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.Unique metabolism of a novel antiviral L-nucleoside analog, 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinaseCell-based and animal models for hepatitis B and C viruses.A mechanistic view of human mitochondrial DNA polymerase gamma: providing insight into drug toxicity and mitochondrial diseaseIdentification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients.Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis.A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.Anti-HBV specific beta-L-2'-deoxynucleosides.A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.Comparison of anti-hepatitis B virus activities of lamivudine and clevudine by a quantitative assay.Rebound of hepatitis B virus replication in HepG2 cells after cessation of antiviral treatmentEmerging therapies of hepatitis B and C.Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucksEmerging treatments in chronic hepatitis B.Review article: Nucleoside analogues for the treatment of chronic hepatitis B.Update on new antivirals under development for the treatment of double-stranded DNA virus infectionsHepatitis B virus reverse transcriptase - Target of current antiviral therapy and future drug development.Clevudine for the treatment of chronic hepatitis B virus infection.Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo.Fluorinated Nucleosides: Synthesis and Biological ImplicationAntiviral treatment of chronic hepatitis B virus infections: the past, the present and the future.Noncompetitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses.Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides.A transient kinetic approach to investigate nucleoside inhibitors of mitochondrial DNA polymerase gamma.Perspectives of biotechnological production of L-ribose and its purification.Nucleoside-based probes for imaging tumor proliferation using positron emission tomography.
P2860
Q27489125-3DEE77A4-A3F7-4558-9C8B-A5EFE2A69C1AQ28344037-512086D1-624C-4F6D-B113-4A06B198CE3DQ28344936-AAA1FA55-2E39-44F5-A542-E31D028629E7Q28345251-F4ED80FA-2B4B-43B5-B7F4-F13D375F113BQ28378787-197FEE5A-4E1D-41B6-BD7F-77539E026733Q28379076-E1E6CAEF-FFD2-4725-8645-CE699A6BE426Q28379171-AB8013E0-D2CA-4CF7-A6F0-AF6B7560B9FCQ31393190-289EA487-D574-4CDE-80D7-EE8E4BBC67F0Q31409503-F7888AA0-F631-4A3E-8868-0259D553BDB9Q31618693-7814D0E6-242B-46B7-B832-287543F733C9Q33267624-477BF6E9-4518-4536-AAAF-925492765A4AQ33549555-DA4C70DF-C02B-46C8-AFC9-A5FC6761405DQ33689987-E9ED071E-D261-4087-81ED-436D65CACE62Q33692618-635FFEC5-78D3-492F-A6F6-1F00FF1A47ADQ33702348-34C13B01-3876-44E0-91EA-68F0DD132DDDQ33756066-E5FA21FF-4D8F-4D5F-B813-EAC33A3F368DQ33826784-DC35EAE5-6DCA-4441-888D-E479AA401735Q33834863-6DA9EE6A-2394-4EE1-8DAD-CDC480C21684Q33977510-E0332FEB-16B5-4BC8-8498-2FB7842CB9A3Q34373564-B3C111B4-008E-416D-B57D-60D8181049F2Q34515984-B5C98115-4661-423C-82D1-864E45A24ED0Q34648598-BEF50AF8-A2BC-478D-9605-2DA2DDE9D323Q34720217-57EF07D2-EB23-4CEE-A1A1-B4A9F403B962Q35001053-5D735BD9-310C-4319-8036-1DBC7E0714F6Q35048263-7736F07D-D82F-4A0D-8EDD-9E149A8AA420Q35138496-83B5A504-77F7-44D1-837A-EA919073F0BAQ35967369-BCD2A1D0-9AB6-4778-BA51-18FBEADBA80CQ35987869-67945C73-5E14-46B0-AFC5-E81712C596D3Q36185647-309CFB0A-6122-4CC1-80DF-04D21BCD973BQ36264766-E0D97612-A531-4B5B-93EF-EBDB9F846E74Q36268376-F0A52C6D-F6BF-46E3-BCF9-68EE9E9FB97DQ36607389-7565E306-DB66-4DD9-BDFE-C3C6B5CEB623Q36974059-53A35370-A97D-465D-842F-39D548EDDD38Q36983856-0F6A5996-6094-4322-9484-EEFB43AC253BQ37124000-7FBB7495-EDC3-4DB2-BFA3-1E4E24948F1DQ37252268-FDDA317A-F638-49B4-9A74-6EC05931A184Q37396435-62CE2D87-811F-417C-9EFE-55F0ECEBD150Q37767303-D6B36CF3-C851-4B35-A6B9-E10734939860Q37923337-27689084-4136-4D4F-BEA9-97DE20FF7DC8Q38166979-6B723462-0819-4BC1-A3F3-9D9B64AA3FD1
P2860
Use of 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@en
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@nl
type
label
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@en
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@nl
prefLabel
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@en
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@nl
P2093
P2860
P356
P1476
Use of 2'-fluoro-5-methyl-beta ...... virus and Epstein-Barr virus.
@en
P2093
J P Sommadossi
K Shanmuganathan
P2860
P304
P356
10.1128/AAC.39.4.979
P407
P577
1995-04-01T00:00:00Z